On Monday, while waiting to see the impact of the vaccine program, financial markets remained watching the increase in cases and hospitalizations in the United States with concern, expecting fresh local lockdown that could slow down the economic recovery.
The political deadlocks that continue to preclude the United States from implementing a new budgetary support plan Congress makes investors anxious as well. They also see strains between Treasury Secretary Steven Mnuchin and the Federal Reserve, with Mnuchin announcing that a number of asset buyback programs set up by the Fed to fight the coronavirus effects would be terminated on 31 December.
On the value hand, the declaration of a high efficacy rate for its vaccine candidate at the end of Phase 3 trial did not really favor Astrazeneca Plc (AZN) which dropped by -1 percent in New York. One of the group’s two vaccination procedures was 90 percent active and the other procedure was effective at 62 percent, an average rate of 70 percent, according to preliminary results reported on Monday.
The vaccine efficacy of rate of AZN is slightly lower than that of Pfizer Inc (PFE)/BioNTech SE (BNTX) (95 percent) and Moderna Inc (MRNA) (94.5 percent) competitors, but quite adequate from a scientific point of view, especially because it is easier to transport Astrazeneca’s vaccine as there is no need for its vaccine to be refrigerated at -70 degrees Celsius.
On NBC, Moncef Slaoui, chief scientific advisor to the White House for overseeing the production of a Covid vaccine, estimated that in December there were enough doses of Pfizer/BioNTech and Moderna vaccines to rapidly vaccinate 20 million Americans. He added that if their vaccine candidate is rapidly accepted by the FDA, the U.S. health authority, the first vaccines could take place as early as December 11 in the United States.